Ascletis Pharma Inc. (1672.HK)
| Previous close | 1.100 |
| Open | 1.090 |
| Bid | 1.060 x 0 |
| Ask | 1.070 x 0 |
| Day's range | 1.050 - 1.090 |
| 52-week range | 1.050 - 2.300 |
| Volume | |
| Avg. volume | 767,414 |
| Market cap | 1.074B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024
Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672, "Ascletis") dedicated to the research and development and commercialization of new drugs in the field of metabolic dysfunction-associated steatohepatitis (MASH), today announced a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2024, held June 5-8, 2024 in Milan, Italy. A copy of the poster is available under the Posters/Publications page of Gannex's website a
- PR Newswire
Ascletis Announces Strategic Decisions on FXR agonist ASC42
Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42.
- PR Newswire
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, the United States.
